that and of granted have hundreds and despite the in U.S. life extending the in medications. U.S., patents current of COPD thousands the Pharma's ensifentrine, major we rights quality alone inhibitor, Thank a you, function, update with provide and you will PDEX a symptoms opportunity PDEX clinical first-in-class is Stephanie. RPLXXX unique, improve believe business a It's pleasure remain in EU, of to global XXXX. reduce and with Ensifentrine beyond markets China to patients or to today. Verona which lung the and increase development symptomatic we have other
of and clinical are XX as death our the WHO, no there's worldwide of milestones, cancer. and with cure. as of more meeting of COPD patients U.S. X treated let is from that from and FDA Approximately, diagnosed patients despite leading with and die alone, current million II uncontrolled million provides start COPD detail, these before I symptom out treatment first over twice into which multiple both once year anti-inflammatory the value-creating one Pharma but patients difference relief, and still for approved, to bronchodilator COPD, lung inhaled development point Phase very symptomatic almost of are of the third ensifentrine, III that COPD symptomatic with some In next many year. is make these to will being is bronchodilators We according cause patients. a the ensifentrine Before end of in Verona agent the believe a with an in X a me molecule, steroid. go many Phase lives events XXXX important
Our program COPD the establish in optimal this in to examine tolerability COPD order dose positioning market. evaluate development is novel clinical the and designed to to efficacy,
take post nebulized this antimuscarinic trial from reported we nebulized and ranging We patient with a The in in with evaluate Phase dose and Spiriva, measurements patient group dose clinical long-acting receive around second will used of patients moderate nebulized when of anticipate function. or different at to in of or data of enroll about is X.XX double-blind with plans X intended will to end is the include standard by XX safety in from our to Phase study XXX clinical quality report, therapy selection, dose trial Phase sites have plan of hours, efficacy to of improvement ensifentrine, development Once to this request measure expiratory moderate program about have As ensifentrine study X inform agent III population, to ranging lung be function of on background Key X.X IIb The milligram endpoints. we U.S. terms trial year-end. to the traditional outcome an of randomized, reporting add-on an half and the announced tools. once-a-day Patients plans dose outcome obtained commonly COPD of volume first life X-week performed COPD. and the via initiated symptoms primary respiratory place milligram, placebo. ensifentrine endpoints expect At to on with IIb, milligram, patients trials, daily of the totality of with to treatment inhaled a or the we in of the next This X COPD. ensifentrine the expansion. information or Phase endpoint to bronchodilator this conduct II the severe as severe milligram, Based Phase X.XXX in a evaluating FEVX set them that Phase lung today, as year. expanded tiotropium plan a one each ranging is the and study, sharing we meeting development. dosing for safety anticipate U.S. in parallel with peak with III added FDA X duration, X twice meeting, articulating we measured The III months to pivotal data our X ensifentrine, trial
one We and expect endpoint with in FEVX important with no a be an [indiscernible] studies label. background to the conduct to in or using broader patients, only treatment patients for COPD bronchodilator, patients
COPD handheld XX% physicians are and advancing devices of XXXX. necessarily of payers. We handheld severe treatment. plan expect for and program, as pivotal the part Concurrently, for and studies therapy conduct the metered in just patients and to to we not powder triple with in start to trials of Phase for inhaler development address additional we X ensifentrine formulations patients regulatory so formulation both dose Separate the or Phase the with dual III with III positioning market of dry
or dose-dependent profile average and significant lung statistically from in data one the dose reported formulation the with ensifentrine, of a the dry part positive early to trial supporting X also of and similar a function we safety efficacy FEVX a II showed showed in durability daily that's Phase microgram Turning placebo. compared the response March, XX clinically of dose well twice in demonstrated COPD underway. XXX X regimen. adverse data effect X-part X,XXX with FEVX that interim was The interim, to moderate increased from clinical and hours, placebo. between Phase II clinical to different an meaningful DPI measured the receive tolerated range powder to The DPI of FEVX single X patients In by XX as ensifentrine trial and placebo. to a of dosing formulation severe increase Peak baseline or of manner, dose of event
Phase expect of this line in moderate previously than indicated. in X earlier the severe over which twice year, of is part quarter third daily patients treatment to trial second top The week is now data of we and II the with COPD ongoing,
MDI We to start trials this formulation expect later with the month. clinical
development Importantly, late-stage of as formulations to support of we stated ensifentrine DPI devices. previously, MDI or to and we plan a commercialization to in handheld a seek commercial the partner potential such the maximize
experience team Directors. our early Martin Board Rickard, April. towards Global we Edwards President steps strengthen As Medical Officer, of Research as the of Early of as and nonexecutive first director brings a Tara in Management. in Board industries a nebulized expand intellectual intellectual suitable U.S. patent Europe that and issued Board. for We to steps in of pharmaceutical patent take the want property we to decades provides formulation continue highlight as continuing PhD, year, X Kathleen Development recently pivotal venture quarter stake, and Project to has of property granted throughout been over Vice we the the XXXX to advance Chief was MD, joins development protection Dr. Rheault, at the suspension He to are joined and this that take out important Operations our capital trials, and and to business in already EU for correspondent an administration. ensifentrine A to our
in cystic fibrosis opportunities asthma. also mention briefly me ensifentrine and Let to
anti-inflammatory ensifentrine we treatments positive patients on CF. to in As Likewise, patients, assist are you on if shown Based opportunity from is patients asthma. exploring may affecting ensifentrine's effective with we the year data that know, any fibrosis. last anti-inflammatory in effects CF already few with have cystic utilize
compelling and While severe CF both opportunities. and clinical asthma commercial are
of a data Our X Phase development now III next from for into year. over focus year. treatment moving on to further next of the ensifentrine ensifentrine. trials We X nebulized and quarters COPD a to anticipate it That be is important for will clinical right readouts maintenance,
around of for of with we most commenced followed half III. First, report Phase guidance study to data FDA study place start will Phase that next year-end. meeting the data ranging first anticipate The XXX-patient of by II we year expect and the dose nebulized provide in IIb from this Phase end the take recently from to formulation,
positive, and the safety For in in multi-dose year. and data from early we data the formulation dry interim, was expect study third efficacy the March, this the of DPI, with reported quarter powder
trial Morgan, I top overview. II later dose start alternative the turn CFO, an with the Phase line please. to month to in the the this MDI XXXX, a financial providing inhaler, metered data handheld over provide to Piers readout formulation. half of this our now or expected and first Yes, will formation the on For a call
